Akeso Inc
HKEX:9926
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.8
76.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Akeso Inc
Intangible Assets
Akeso Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Akeso Inc
HKEX:9926
|
Intangible Assets
ÂĄ8.5m
|
CAGR 3-Years
90%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Intangible Assets
ÂĄ982.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Intangible Assets
ÂĄ642.7m
|
CAGR 3-Years
40%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Intangible Assets
ÂĄ227.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Intangible Assets
ÂĄ1.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
||
Imeik Technology Development Co Ltd
SZSE:300896
|
Intangible Assets
ÂĄ114.9m
|
CAGR 3-Years
123%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
Akeso Inc
Glance View
Akeso Inc. is an innovative biopharmaceutical company that has carved out a distinctive niche in the treatment of cancer and autoimmune diseases. With its headquarters in Zhuhai, China, Akeso is focused on developing cutting-edge therapies driven by its proprietary bispecific antibody platform. This platform allows the company to create multifunctional antibodies that can simultaneously target different pathways, potentially enhancing the effectiveness of treatments while minimizing side effects. Akeso's lead product, the PD-1 monoclonal antibody, AK104, has been making significant strides with promising results in clinical trials, positioning the company as a formidable player in the competitive oncology landscape. As the global demand for novel therapeutics grows, Akeso is not just resting on its laurels. The company has an impressive pipeline of candidates that address various hematological malignancies and autoimmune disorders, indicating a strong commitment to broadening its therapeutic reach. Additionally, Akeso's strategic partnerships, including collaborations with major global pharmaceutical firms for development and commercialization, bolster its potential for growth and market penetration. For investors, Akeso represents a compelling opportunity as it navigates the complexities of drug development and regulatory approval, poised to transform the landscape of treatment options available to patients and carve out a lasting presence in the biopharmaceutical sector.
See Also
What is Akeso Inc's Intangible Assets?
Intangible Assets
8.5m
CNY
Based on the financial report for Dec 31, 2023, Akeso Inc's Intangible Assets amounts to 8.5m CNY.
What is Akeso Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
112%
Over the last year, the Intangible Assets growth was 0%. The average annual Intangible Assets growth rates for Akeso Inc have been 90% over the past three years , 112% over the past five years .